Search

Displaying results 4181 - 4190 of 7059 in total
  1. Drug

    Emapalumab

    go.drugbank.com/drugs/DB14724
    ApprovedInvestigational

    Emapalumab development was sponsored by NovImmune SA, further developed by Sobi and FDA approved on November 20, 2018. … Emapalumab, also known as NI-0501, is a fully human monoclonal antibody that targets interferon gamma.

  2. Drug

    Pamidronic acid

    go.drugbank.com/drugs/DB00282
    ApprovedInvestigational

    [A203111] Pamidronic acid was granted FDA approval on 31 October 1991.[L13835] … Pamidronic acid is a second generation, nitrogen containing bisphosphonate similar to [neridronic acid] and [alendronic acid].[A203111] Pamidronic acid was first described in the literature in 1977.

  3. Drug

    Colchicine

    go.drugbank.com/drugs/DB01394
    ApprovedInvestigational

    Colchicine is an alkaloid drug derived from a plant belonging to the Lily family, known as _Colchicum autumnale_, or "autumn crocus."[A183611] Its use was first approved by the FDA in 1961.

    Products: Euro-colchicine
  4. Drug

    Testosterone propionate

    go.drugbank.com/drugs/DB01420
    ApprovedInvestigationalVet approvedWithdrawn

    Testosterone propionate is a slower-releasing anabolic steroid with a short half-life. … [T83] Testosterone propionate was developed initially by Watson labs, and FDA approved on February 5, 1974.

  5. Drug

    Copanlisib

    go.drugbank.com/drugs/DB12483
    ApprovedInvestigational

    Copanlisib is a selective pan-Class I phosphoinositide 3-kinase (PI3K) inhibitor with preferential activity against the alpha and delta isoforms. … [A261730] Copanlisib was granted accelerated approval by the FDA in September 2017 for the treatment of follicular lymphoma.[A261725]

    Categories: P-glycoprotein substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index
  6. Drug

    Amredobresib

    go.drugbank.com/drugs/DB21566
    Investigational

    Amredobresib has a monoisotopic molecular weight of 467.25 Da. … Amredobresib is a small molecule drug.

  7. Drug

    Tegtociclib

    go.drugbank.com/drugs/DB21635
    Investigational

    Tegtociclib has a monoisotopic molecular weight of 404.22 Da. … Tegtociclib is a small molecule drug. The usage of the INN stem '-ciclib' in the name indicates that Tegtociclib is a cyclin dependant kinase inhibitor.

  8. Drug

    Frespaciguat

    go.drugbank.com/drugs/DB21683
    Investigational

    Frespaciguat has a monoisotopic molecular weight of 608.14 Da. … Frespaciguat is a small molecule drug. The usage of the INN stem '-ciguat' in the name indicates that Frespaciguat is a guanylate cyclase activator and stimulator.

  9. Drug

    Afamitresgene autoleucel

    go.drugbank.com/drugs/DB18592
    ApprovedInvestigational

    Afamitresgene autoleucel is a melanoma-associated antigen A4 (MAGE-A4)-directed genetically modified autologous T cell immunotherapy product consisting of CD4 and CD8 positive T cells transduced with a … [L51114] On August 2, 2024, the FDA granted the accelerated approval of afamitresgene autoleucel, making it the first FDA-approved TCR gene therapy and the first gene therapy for the treatment of synovial

    Synonyms: LEUKAPHERESIS, TRANSDUCED WITH AN HIV-DERIVED SELF-INACTIVATING (SIN) LENTIVIRAL VECTOR, ENCODING AN ENHANCED-AFFINITY T CELL RECEPTOR (TCR) SPECIFIC FOR THE HUMAN MELANOMA ANTIGEN A4 (MAGE FAMILY MEMBER A4, A
  10. Drug

    Nesvategrast

    go.drugbank.com/drugs/DB19337
    Investigational

    Nesvategrast is under investigation in clinical trial NCT05409235 (Nesvategrast (OTT166) in Diabetic Retinopathy (DR)).